Search hospitals > Missouri > Liberty
BVL Clinical Research
Claim this profileLiberty, Missouri 64068
Conducts research for Ulcerative Colitis
Conducts research for Psychogenic Colitis
Conducts research for Ulcer
Conducts research for Crohn's Disease
Conducts research for Colitis
5 reported clinical trials
1 medical researcher
Summary
BVL Clinical Research is a medical facility located in Liberty, Missouri. This center is recognized for care of Ulcerative Colitis, Psychogenic Colitis, Ulcer, Crohn's Disease, Colitis and other specialties. BVL Clinical Research is involved with conducting 5 clinical trials across 5 conditions. There are 1 research doctors associated with this hospital, such as Christopher Bartalos, MD.Top PIs
Clinical Trials running at BVL Clinical Research
Ulcerative Colitis
Crohn's Disease
Psychogenic Colitis
Ulcer
Colitis
Vedolizumab + Tofacitinib
for Ulcerative Colitis
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the double treatment. All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone for an additional 44 weeks. Each participant will be followed up for at least 26 weeks after the last dose of vedolizumab.
Recruiting3 awards Phase 47 criteria
RO7790121
for Ulcerative Colitis
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Recruiting1 award Phase 33 criteria
ABX464 Maintenance Therapy
for Ulcerative Colitis
This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors\]. This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106.
Recruiting1 award Phase 3
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at BVL Clinical Research?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.